The Journal of Allergy and Clinical Immunology
Volume 124, Issue 5 , Pages 921-927 , November 2009

Recent asthma exacerbations predict future exacerbations in children with severe or difficult-to-treat asthma

  • Tmirah Haselkorn, PhD

      Affiliations

    • Genentech, Inc, South San Francisco, Calif
    • Corresponding Author InformationReprint requests: Tmirah Haselkorn, PhD, Genentech, Inc, 1 DNA Way, MS 58B, South San Francisco, CA 94080.
    • ,
  • Robert S. Zeiger, MD, PhD

      Affiliations

    • Kaiser-Permanente Medical Center, San Diego, Calif
    • ,
  • Bradley E. Chipps, MD

      Affiliations

    • Capital Allergy and Respiratory Disease Center, Sacramento, Calif
    • ,
  • David R. Mink, MS

      Affiliations

    • ICON Clinical Research, San Francisco, Calif
    • ,
  • Stanley J. Szefler, MD

      Affiliations

    • National Jewish Health, Denver, Colo
    • ,
  • F. Estelle R. Simons, MD

      Affiliations

    • University of Manitoba, Winnipeg, Manitoba, Canada
    • ,
  • Marc Massanari, PharmD

      Affiliations

    • Novartis Pharmaceuticals Corp, East Hanover, NJ
    • ,
  • James E. Fish, MD

      Affiliations

    • Genentech, Inc, South San Francisco, Calif

Received 1 April 2009 ,Revised 22 August 2009 ,Accepted 3 September 2009.

References 

  1. Bousquet J, Bousquet PJ, Godard P, Daures JP. The public health implications of asthma. Bull World Health Organ. 2005;83:548–554
  2. Jenkins HA, Cherniack R, Szefler SJ, Covar R, Gelfand EW, Spahn JD. A comparison of the clinical characteristics of children and adults with severe asthma. Chest. 2003;124:1318–1324
  3. Bloom B, Dey AN, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2005. Vital Health Stat. 2006;10:1–84
  4. Sorkness RL, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Chung KF, et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol. 2008;104:394–403
  5. Sullivan SD. Asthma in the United States: recent trends and current status. J Manag Care Pharm. 2003;9(suppl 5):3–7
  6. Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F, et al. Asthma severity and medical resource utilisation. Eur Respir J. 2004;23:723–729
  7. Vollmer WM, Markson LE, O'Connor E, Frazier EA, Berger M, Buist AS. Association of asthma control with health care utilization: a prospective evaluation. Am J Respir Crit Care Med. 2002;165:195–199
  8. Chipps BE, Szefler SJ, Simons FE, Haselkorn T, Mink DR, Deniz Y, et al. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2007;119:1156–1163
  9. Moore WC, Peters SP. Severe asthma: an overview. J Allergy Clin Immunol. 2006;117:487–494
  10. Weinmann S, Kamtsiuris P, Henke KD, Wickman M, Jenner A, Wahn U. The costs of atopy and asthma in children: assessment of direct costs and their determinants in a birth cohort. Pediatr Allergy Immunol. 2003;14:18–26
  11. Ungar WJ, Coyte PC. Prospective study of the patient-level cost of asthma care in children. Pediatr Pulmonol. 2001;32:101–108
  12. Herjavecz I, Nagy GB, Gyurkovits K, Magyar P, Dobos K, Nagy L, et al. Cost, morbidity, and control of asthma in Hungary: the Hunair Study. J Asthma. 2003;40:673–681
  13. Wenzel S, Szefler SJ. Managing severe asthma. J Allergy Clin Immunol. 2006;117:508–511
  14. Stoloff SW, Boushey HA. Severity, control, and responsiveness in asthma. J Allergy Clin Immunol. 2006;117:544–548
  15. Dolan CM, Fraher KE, Bleecker ER, Borish L, Chipps B, Hayden ML, et al. Design and baseline characteristics of The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2004;92:32–39
  16. Miller MK, Lee JH, Miller DP, Wenzel SE. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med. 2007;101:481–489
  17. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program Expert Panel report 2: guidelines for the diagnosis and management of asthma. Available at Bethesda (MD): National Institutes of Health; 1997;http://www.nhlbi.nih.gov/guidelines/archives/epr-2/asthgdln_archive.pdfAccessed March 16, 2009
  18. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program Expert Panel report 3: guidelines for the diagnosis and management of asthma. Full report. Available at Bethesda (MD): National Institutes of Health; 2007;http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htmAccessed March 16, 2009
  19. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res. 1996;5:35–46
  20. Haselkorn T, Fish JE, Zeiger RS, Szefler SJ, Miller DP, Chipps BE, et al. TENOR Study Group Consistently very poorly controlled asthma as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) Study. J Allergy Clin Immunol. 2009;124:895–902
  21. Zeiger RS, Chipps BE, Haselkorn T, Rasouliyan L, Simons FER, Fish JE. Comparison of asthma exacerbations in pediatric and adult patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2009;124:1106-8
  22. Covar RA, Szefler SJ, Zeiger RS, Sorkness CA, Moss M, Mauger DT, et al. Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children. J Allergy Clin Immunol. 2008;122:741–747
  23. Fuhlbrigge AL, Weiss ST, Kuntz KM, Paltiel AD. Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma. Pediatrics. 2006;118:e347–e355
  24. McCoy K, Shade DM, Irvin CG, Mastronarde JG, Hanania NA, Castro M, et al. Predicting episodes of poor asthma control in treated patients with asthma. J Allergy Clin Immunol. 2006;118:1226–1233
  25. Crain EF, Walter M, O'Connor GT, Mitchell H, Gruchalla RS, Kattan M, et al. Home and allergic characteristics of children with asthma in seven U.S. urban communities and design of an environmental intervention: the Inner-City Asthma Study. Environ Health Perspect. 2002;110:939–945
  26. Wever-Hess J, Kouwenberg JM, Duiverman EJ, Hermans J, Wever AM. Risk factors for exacerbations and hospital admissions in asthma of early childhood. Pediatr Pulmonol. 2000;29:250–256
  27. Fitzpatrick AM, Gaston BM, Erzurum SC, Teague WG. Features of severe asthma in school-age children: atopy and increased exhaled nitric oxide. J Allergy Clin Immunol. 2006;118:1218–1225
  28. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108:E36
  29. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006;(2):CD003559
  30. Lozano P, Connell FA, Koepsell TD. Use of health services by African-American children with asthma on Medicaid. JAMA. 1995;274:469–473
  31. Kwong KY, Morphew T, Scott L, Guterman J, Jones CA. Asthma control and future asthma-related morbidity in inner-city asthmatic children. Ann Allergy Asthma Immunol. 2008;101:144–152
  32. Moorman JE, Rudd RA, Johnson CA, King M, Minor P, Bailey C, et al. National surveillance for asthma—United States, 1980-2004. MMWR Surveill Summ. 2007;56:1–54
  33. Chan MT, Leung DY, Szefler SJ, Spahn JD. Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma. J Allergy Clin Immunol. 1998;101:594–601
  34. Robertson CF, Rubinfeld AR, Bowes G. Pediatric asthma deaths in Victoria: the mild are at risk. Pediatr Pulmonol. 1992;13:95–100
  35. Sorkness CA, Lemanske RF, Mauger DT, Boehmer SJ, Chinchilli VM, Martinez FD, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol. 2007;119:64–72

 Support for third-party medical writing assistance was provided by Genentech USA, Inc, and Novartis Pharmaceuticals Corp.

 Disclosure of potential conflict of interest: T. Haselkorn is a consultant for Genentech. R. S. Zeiger is a consultant for Aerocrine, AstraZeneca, Dynavax, Genentech, GlaxoSmithKline, Merck, Novartis, and Schering-Plough and has received research support from AstraZeneca, Merck, GlaxoSmithKline, TEVA, Aerocrine, and the National Heart, Lung, and Blood Institute. B. E. Chipps is an advisor and/or speakers' bureau member for Alcon, Aventis, Genentech, AstraZeneca, Boehringer, GlaxoSmithKline, MedPoint, Novartis, Pfizer, Schering, Sepracor, and Merck and has received support for research and/or educational activities from Alcon, Aventis, Genentech, AstraZeneca, GlaxoSmithKline, MedPoint, Novartis, Schering, Sepracor, and Merck. D. R. Mink is an employee of ICON Clinical Research, which receives research funding from Genentech. S. J. Szefler is a consultant for GlaxoSmithKline, Genentech, and Merck and has received research support from the National Institutes of Health, the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, Ross Pharmaceuticals, and GlaxoSmithKline. F. E. R. Simons has received research support from the Canadian Institutes of Health Research and has consulted for Genentech. M. Massanari is an employee of Novartis. J. E. Fish is an employee of Genentech.

PII: S0091-6749(09)01335-9

doi: 10.1016/j.jaci.2009.09.006

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 5 , Pages 921-927 , November 2009

Article Tools

* Image Usage & Resolution